Genetic tests can indicate whether a given person is at risk for certain diseases. But recent work by MIT scientists suggests that it may soon be possible to test how well people will tolerate toxic compounds, as well. Such tests could even enable doctors to predict how a given patient will respond to specific chemotherapy drugs.
The scientists, led by Leona Samson, director of MIT’s Center for Environmental Health Sciences and professor of biological engineering and biology, first measured gene expression in cells from 24 healthy people in a genetically and ethnically diverse population sample. Then they exposed these cell lines to a DNA-damaging agent, MNNG. By comparing gene expression in the four most sensitive and the four most resistant cell lines, they were able to zero in on 48 key genes correlated with MNNG sensitivity. By measuring the activity of these standouts alone, without examining every gene, they found that they could predict, with 94 percent accuracy, whether any of the remaining cell lines would stand up to the toxic compound. Because the cell lines came from a diverse group of subjects, the test should be widely applicable in the general population.
Samson says that the group already knew of a dozen genes linked to MNNG resistance, but this study scanned for all potential candidates, identifying 450 that were differently expressed. “We found an incredible number,” she says. “That made us realize that there are a whole lot of other things going on that are important for protecting against damaging agents.”
MNNG was an ideal test subject because it’s similar to toxic compounds found in common chemotherapy drugs and tobacco smoke. Now Samson’s group is expanding the study to chemotherapeutic agents. She hopes that in the long run, the group’s work will lead to tests that can determine which drugs will be most effective in killing a particular tumor and, just as important, how well a patient’s healthy cells will resist that compound’s toxic action. “You want to kill the tumor but you don’t want to kill the person,” Samson says. And while she’s hesitant to speculate, she’s hopeful about the potential of the work: “The important thing is finding the most effective treatment for each individual patient. It’s really thinking toward the possibility of personalized medicine.”
The inside story of how ChatGPT was built from the people who made it
Exclusive conversations that take us behind the scenes of a cultural phenomenon.
How Rust went from a side project to the world’s most-loved programming language
For decades, coders wrote critical systems in C and C++. Now they turn to Rust.
Design thinking was supposed to fix the world. Where did it go wrong?
An approach that promised to democratize design may have done the opposite.
Sam Altman invested $180 million into a company trying to delay death
Can anti-aging breakthroughs add 10 healthy years to the human life span? The CEO of OpenAI is paying to find out.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.